This miRNA has been associated with drug resistance, and it is an essential driver of KMT2A-AFF1 leukemia, integrated with the aberrant overexpression of key downstream targets, i.e., the antiapoptotic factor BCL2 and proto-oncogene MYC [195,196]. This evidence concerns the gene MYC and leukemia.